Market capitalization | $75.15m |
Enterprise Value | $-31.84m |
P/E (TTM) P/E ratio | 5.66 |
EV/FCF (TTM) EV/FCF | 0.36 |
EV/Sales (TTM) EV/Sales | -0.25 |
P/S ratio (TTM) P/S ratio | 0.59 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 33.66% |
Revenue (TTM) Revenue | $126.62m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a CytomX Therapeutics, Inc. forecast:
7 Analysts have issued a CytomX Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 127 127 |
34%
34%
|
|
Gross Profit | 125 125 |
41%
41%
|
|
EBITDA | 8.55 8.55 |
1,029%
1,029%
|
EBIT (Operating Income) EBIT | 6.71 6.71 |
198%
198%
|
Net Profit | 14 14 |
236%
236%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Sean McCarthy |
Employees | 122 |
Founded | 2010 |
Website | www.cytomx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.